# Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

> **NCT06200103** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 236 (estimated)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Stage IVB Prostate Cancer AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Scan
- **OTHER:** Clinical Observation
- **PROCEDURE:** Computed Tomography
- **OTHER:** Gallium Ga 68 Gozetotide
- **DRUG:** Lutetium Lu 177 Vipivotide Tetraxetan
- **PROCEDURE:** Positron Emission Tomography
- **OTHER:** Questionnaire Administration
- **PROCEDURE:** Single Photon Emission Computed Tomography

## Key facts

- **NCT ID:** NCT06200103
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-03
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06200103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06200103, "Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06200103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*